115401-39-3

Upstream product

• 111-30-8 Glutaraldehyde 
• 28469-52-5 6-hydroxy-cyclohex-1-enecarboxylic acid ethyl ester 
• 108-24-7 acetic anhydride 

Downstream Products

• 115413-77-9 Isopropyl-6 ethoxycarbonyl-1 cyclohexene 
• 115413-73-5 n-Butyl-6 ethoxycarbonyl-1 cyclohexene 
• 115413-80-4 (Ethoxycarbonyl-1 cyclohexene yl-6)-2 methyl-2 acetate d'ethyle 
• 115413-79-1 6-phenylcyclohex-1-ene-1-carboxylic methyl ester 
• 144901-82-6 (R)-2-carbethoxy-2-cyclohexen-1-ol 
• 144901-84-8 (S)-6-Acetoxy-cyclohex-1-enecarboxylic acid ethyl ester 
• 144901-80-4 (R)-6-Acetoxy-cyclohex-1-enecarboxylic acid ethyl ester 
• 1426151-34-9 C₈H₁₃NO₂ 
• 1426151-43-0 6-{[4,4-bis(3-methylthien-2-yl)but-3-enyl]methylamino}cyclohex-1-enecarboxylic acid ethyl ester 
• 1426151-33-8 C₂₂H₂₇NO₂S₂*ClH 
• 1426151-44-1 6-methylaminocyclohex-1-enecarboxylic acid ethyl ester 
• 1028450-05-6 ethyl 6-mercaptocyclohex-1-ene-1-carboxylate 
• 1028450-04-5 ethyl 6-(acetylsulfanyl)cyclohex-1-ene-1-carboxylate 
• 28469-52-5 6-hydroxy-cyclohex-1-enecarboxylic acid ethyl ester 

Relevant academic research and scientific papers

CYCLIC COMPOUNDS

The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

Selective mGAT2 (BGT-1) GABA uptake inhibitors: Design, synthesis, and pharmacological characterization

β-Amino acids sharing a lipophilic diaromatic side chain were synthesized and characterized pharmacologically on mouse GABA transporter subtypes mGAT1-4. The parent amino acids were also characterized. Compounds 13a, 13b, and 17b displayed more than 6-fold selectivity for mGAT2 over mGAT1. Compound 17b displayed anticonvulsive properties inferring a role of mGAT2 in epileptic disorders. These results provide new neuropharmacological tools and a strategy for designing subtype selective GABA transport inhibitors.

Enantiocomplementary Synthesis of Functionalized Cycloalkenol Building Blocks Using Lipase

Racemic 2-carbethoxy-2-cyclopenten-1-ol and racemic 2-carbethoxy-2-cyclohexen-1-ol afforded the corresponding (R)-acetates leaving the corresponding (S)-alcohols unchanged upon treatment with v

SUBSTITUTION NUCLEOPHILE D'ACETATES DE CYCLENOLS ALLYLIQUES FONCTIONNELS PAR DES ORGANOMETALLIQUES EN PRESENCE DE SELS CUIVREUX. APPLICATION A UNE SYNTHESE RAPIDE DE LA (+/-) MITSUGASHIWALACTONE

Substitution of functional allylic cycloalkenol acetates by Grignard reagents (primary, secondary, tertiary-alkyl, vinyl, aryl) in the presence of a catalytic amount (2.5percent equivalent) of cuprous iodide at low temperature, gives high yields of various functional α-substituted cycloalkenes.The reaction can be applied to lithium enolates of esters and need no catalyst, but may be performed with HMPA as cosolvent.It is illustrated by a short (6 steps) and efficient total selective synthesis of (+/-)-mitsugashiwalactone from 2,5-dimethoxytetrahydrofuran with 33percent overall yield.